The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Prelude Therapeutics Incorporated(NASDAQ:PRLD)


Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid...
Website: http://www.preludetx.com
Founded: 2016
Full Time Employees: 55
CEO: Krishna Vaddi
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Prelude Therapeutics Days Payable Outstanding ttm (DPO)
Prelude Therapeutics Op Cashflow Per Share ttm
Prelude Therapeutics Free Cashflow Per Share ttm
Prelude Therapeutics Cash Per Share ttm
Prelude Therapeutics (GAAP) P/E ratio ttm
Prelude Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.